Daisuke Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daisuke Ito has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Fumihiko Urabe
Department of Urology The Jikei University School of Medicine Tokyo Japan
2 shared publications - Akihiko Fukagawa
Department of Pathology, Graduate School of Medicine The University of Tokyo Tokyo Japan
1 shared publication Eisuke Tomiyama
Department of Urology, Graduate School of Medicine The University of Osaka Osaka Japan
1 shared publicationGenki Okumura
1 shared publicationGenshiro Fukuchi
1 shared publication- Hiroki Ishihara
Department of Urology Tokyo Women's Medical University Shinjuku‐ku Tokyo Japan
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (10) , 598-606
Intravesical recurrence is associated with increased Treg and exhausted CD8+ T cells in upper tract urothelial carcinoma
- 17 August 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (10) , 598-606
Open AccessIntravesical recurrence is associated with increased Treg and exhausted CD8+ T cells in upper tract urothelial carcinoma
- 14 January 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (1) , e70341
Translational Advances in Urothelial Carcinoma: From Bench to Bedside
Urothelial carcinoma (UC), encompassing both bladder cancer and upper tract UC, is a biologically heterogeneous malignancy that has long complicated patient stratification and therapeutic prediction. Recent genomic and transcriptomic analyses, however, have delineated reproducible molecular subtypes across non‐muscle‐invasive and muscle‐invasive disease. These classification frameworks have refined biological understanding and improved both risk stratification and treatment selection. Emerging evidence also indicates that genomic alterations, such as FGFR3 mutations, may confer distinct immunologic phenotypes within specific transcriptomic contexts, thereby challenging prior assumptions. The advent of immune checkpoint inhibitors has transformed UC management, yet variable response rates underscore the complexity of the tumor microenvironment (TME). Single‐cell and spatial analyses have identified immune‐inflamed, ‐desert, and ‐excluded TME subtypes, with cancer‐associated fibroblasts playing a key role in immune exclusion and therapeutic resistance. Liquid biopsy, particularly circulating tumor DNA, has demonstrated utility for real‐time disease monitoring, minimal residual disease detection, and treatment stratification, as highlighted in trials such as IMvigor010 and IMvigor011. Urinary extracellular vesicles also represent promising non‐invasive biomarkers, though further standardization is required. In addition, novel therapeutic strategies—including antibody‐drug conjugates, gene therapies, and sustained‐release delivery systems—are broadening treatment options across disease stages. Collectively, these translational advances mark a paradigm shift toward precision immuno‐oncology in UC. Nonetheless, successful clinical implementation will require prospective validation, optimized analytical platforms, and sustained physician‐scientist engagement to translate these discoveries into improved patient outcomes. This review provides a comprehensive overview of recent progress in UC translational research, with a focus on genomic and transcriptomic insights, the evolving role of immunotherapy, advances in liquid biopsy, and the development of novel therapeutics.
- 14 January 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (1) , e70341
Translational Advances in Urothelial Carcinoma: From Bench to Bedside
Urothelial carcinoma (UC), encompassing both bladder cancer and upper tract UC, is a biologically heterogeneous malignancy that has long complicated patient stratification and therapeutic prediction. Recent genomic and transcriptomic analyses, however, have delineated reproducible molecular subtypes across non‐muscle‐invasive and muscle‐invasive disease. These classification frameworks have refined biological understanding and improved both risk stratification and treatment selection. Emerging evidence also indicates that genomic alterations, such as FGFR3 mutations, may confer distinct immunologic phenotypes within specific transcriptomic contexts, thereby challenging prior assumptions. The advent of immune checkpoint inhibitors has transformed UC management, yet variable response rates underscore the complexity of the tumor microenvironment (TME). Single‐cell and spatial analyses have identified immune‐inflamed, ‐desert, and ‐excluded TME subtypes, with cancer‐associated fibroblasts playing a key role in immune exclusion and therapeutic resistance. Liquid biopsy, particularly circulating tumor DNA, has demonstrated utility for real‐time disease monitoring, minimal residual disease detection, and treatment stratification, as highlighted in trials such as IMvigor010 and IMvigor011. Urinary extracellular vesicles also represent promising non‐invasive biomarkers, though further standardization is required. In addition, novel therapeutic strategies—including antibody‐drug conjugates, gene therapies, and sustained‐release delivery systems—are broadening treatment options across disease stages. Collectively, these translational advances mark a paradigm shift toward precision immuno‐oncology in UC. Nonetheless, successful clinical implementation will require prospective validation, optimized analytical platforms, and sustained physician‐scientist engagement to translate these discoveries into improved patient outcomes. This review provides a comprehensive overview of recent progress in UC translational research, with a focus on genomic and transcriptomic insights, the evolving role of immunotherapy, advances in liquid biopsy, and the development of novel therapeutics.
- 7 May 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (8) , 932-943
Translational Research Bridging Basic and Clinical Insights in Renal Cell Carcinoma: A Collaborative Review and Future Directions
Despite significant progress in the diagnosis and treatment of renal cell carcinoma (RCC), approximately 20% of patients present with metastatic disease, and up to 30% of patients with localized tumors experience recurrence following nephrectomy. Although immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs) have improved clinical outcomes, treatment resistance and refractoriness remain critical challenges. Genomic profiling has identified alterations in several kidney cancer‐associated genes, including VHL and chromatin remodeling genes, refining the classification of RCCs and revealing novel therapeutic targets such as hypoxia‐inducible factor (HIF)‐2α and metabolic pathways. Immunologically, RCCs exhibit trends opposite to those observed in other types of cancer, such as melanoma and lung cancer, in that high tumor mutation burden and high CD8+ T cell infiltration in RCCs do not predict better responses to ICIs. Combination therapies integrating ICIs and VEGFR‐TKIs have shown greater treatment efficacy, but overcoming immune resistance remains an urgent priority. Liquid biopsy technologies, including assays of circulating tumor DNA and extracellular vesicles, are emerging as minimally invasive tools for early detection, treatment monitoring, and recurrence prediction. Liquid biopsy approaches that Integrate genomic and transcriptomic profiling may provide comprehensive tumor characterization and suggest personalized treatment strategies. This review explores recent advances in basic and translational research, emphasizing genomic analyses, dissection of tumor‐immune microenvironments, and liquid biopsy techniques that can reshape RCC diagnostics and therapeutics. Multidisciplinary collaboration supported by high‐quality biospecimens and robust clinical datasets is essential to advance translational research and improve patient outcomes.
- 7 May 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (8) , 932-943
Translational Research Bridging Basic and Clinical Insights in Renal Cell Carcinoma: A Collaborative Review and Future Directions
Despite significant progress in the diagnosis and treatment of renal cell carcinoma (RCC), approximately 20% of patients present with metastatic disease, and up to 30% of patients with localized tumors experience recurrence following nephrectomy. Although immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs) have improved clinical outcomes, treatment resistance and refractoriness remain critical challenges. Genomic profiling has identified alterations in several kidney cancer‐associated genes, including VHL and chromatin remodeling genes, refining the classification of RCCs and revealing novel therapeutic targets such as hypoxia‐inducible factor (HIF)‐2α and metabolic pathways. Immunologically, RCCs exhibit trends opposite to those observed in other types of cancer, such as melanoma and lung cancer, in that high tumor mutation burden and high CD8+ T cell infiltration in RCCs do not predict better responses to ICIs. Combination therapies integrating ICIs and VEGFR‐TKIs have shown greater treatment efficacy, but overcoming immune resistance remains an urgent priority. Liquid biopsy technologies, including assays of circulating tumor DNA and extracellular vesicles, are emerging as minimally invasive tools for early detection, treatment monitoring, and recurrence prediction. Liquid biopsy approaches that Integrate genomic and transcriptomic profiling may provide comprehensive tumor characterization and suggest personalized treatment strategies. This review explores recent advances in basic and translational research, emphasizing genomic analyses, dissection of tumor‐immune microenvironments, and liquid biopsy techniques that can reshape RCC diagnostics and therapeutics. Multidisciplinary collaboration supported by high‐quality biospecimens and robust clinical datasets is essential to advance translational research and improve patient outcomes.